Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P28472

UPID:
GBRB3_HUMAN

ALTERNATIVE NAMES:
GABA(A) receptor subunit beta-3

ALTERNATIVE UPACC:
P28472; B7Z2W1; B7Z825; F5H3D2; H7BYV8; Q14352; Q96FM5

BACKGROUND:
The Gamma-aminobutyric acid receptor subunit beta-3, a key component of the GABA(A) receptor, is vital for inhibitory neurotransmission in the brain. It is involved in the formation of GABAergic synapses and acts as a GABA-gated ion channel. Additionally, it serves as a histamine receptor, playing roles in somatosensation and the generation of antinociception.

THERAPEUTIC SIGNIFICANCE:
Associated with neurological diseases such as Epilepsy, childhood absence 5, and Developmental and epileptic encephalopathy 43, Gamma-aminobutyric acid receptor subunit beta-3 is a critical target for drug discovery. Its involvement in these diseases underscores the potential for developing new therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.